Answers are grounded in this paper and cite their sources.
Adiponectin was identified as an adipocytokine in the human adipose tissue cDNA library. It has antiatherosclerotic and antidiabetic properties in experimental studies, and its blood levels are low in obesity, diabetes, cardiovascular diseases, and metabolic syndrome. Several studies have reported that weight reduction in massively obese subjects is associated with a rise in serum adiponectin (APN) concentration (1–3). However, the relationship between changes in APN and BMI, waist circumference (WC), and visceral fat accumulation (VFA) in general population has not been reported. The present study investigated 1-year change in APN (ΔAPN) in relation to changes in BMI (ΔBMI), WC …
No takes yet. Share an insight, caveat, or question.
Okauchi et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: